BibTex format
@article{Chadeau,
author = {Chadeau, M and Wang, H and Eales, O and Haw, D and Bodinier, B and Whitaker, M and Walters, C and Ainslie, K and Atchison, C and Fronterre, C and Diggle, P and Page, A and Trotter, A and Ashby, D and Barclay, W and Taylor, G and Cooke, G and Ward, H and Darzi, A and Riley, S and Donnelly, C and Elliott, P},
journal = {The Lancet Respiratory Medicine},
title = {Randomised community surveys of SARS-CoV-2 infection and vaccine effectiveness in England: REACT-1 study.},
url = {http://hdl.handle.net/10044/1/93140},
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Background: England experienced a third wave of the COVID-19 epidemic from end May 2021 coinciding with the rapid spread of Delta variant despite high levels of vaccination among adults. Vaccination rates (single-dose) are lower among children aged 16-17 and 12-15 years whose vaccination in England commenced in August and September respectively. Methods: The REACT-1 study involves a series of random cross-sectional surveys in the general population of England aged 5 years and over. Using RT-PCR swab-positivity data from (N=100,527) participants with valid swabs in round 14 (9 to 27 September 2021), we estimated community-based prevalence of SARS-CoV-2 and vaccine effectiveness against infection by combining data with round 13 (24 June to 12 July 2021, N=172,862).Findings: During September 2021 we estimated a mean RT-PCR positivity rate of 0.83% (0.76%, 0.89%) with a reproduction number R overall of 1.03 (0.94, 1.14). Among the 475 sequenced positive swabs, all were Delta variant; 22 (4.63%) included the Y145H mutation in the spike protein associated with the AY.4 sub-lineage, and there was one E484K mutation. Age, region, key worker status, and household size jointly contributed to the risk of swab-positivity. The highest weighted prevalence was observed among children aged 5-12 years at 2.32% (1.96%, 2.73%) and 13-17 years at 2.55% (2.11%, 3.08%). The epidemic grew in those aged 5-11 years with R of 1.42, but decreased in those aged 18-54. At ages 18-64 years, the adjusted vaccine effectiveness against infection was 62.8% (49.3%, 72.7%) after two doses compared to unvaccinated people, for all vaccines combined, and 44.8% (22.5%, 60.7%) and 71.3% (56.6%, 81.0%) for AstraZeneca and Pfizer-BioNTech, respectively. At ages >18 years, weighted prevalence of swab-positivity was 0.35% (0.31%, 0.40%) if second dose was <3 months before their swab but 0.55% (0.50%, 0.61%) for those who received their second dose 3-6 months prior, compared to 1.76% (1.60%, 1.95%) among
AU - Chadeau,M
AU - Wang,H
AU - Eales,O
AU - Haw,D
AU - Bodinier,B
AU - Whitaker,M
AU - Walters,C
AU - Ainslie,K
AU - Atchison,C
AU - Fronterre,C
AU - Diggle,P
AU - Page,A
AU - Trotter,A
AU - Ashby,D
AU - Barclay,W
AU - Taylor,G
AU - Cooke,G
AU - Ward,H
AU - Darzi,A
AU - Riley,S
AU - Donnelly,C
AU - Elliott,P
SN - 2213-2600
TI - Randomised community surveys of SARS-CoV-2 infection and vaccine effectiveness in England: REACT-1 study.
T2 - The Lancet Respiratory Medicine
UR - http://hdl.handle.net/10044/1/93140
ER -
